2
ALL1
Danone1
Wanbury LimitedYear
2
ALL1
20221
2020DEALS // DEV.
2
ALL1
Deals1
DevelopmentsCountry
2
ALL1
FRANCE1
INDIA2
ALL1
Cipla1
Not ApplicableTherapeutic Area
2
ALL2
HematologyStudy Phase
2
ALL2
ApprovedDeal Type
1
ALL1
AcquisitionProduct Type
2
ALL2
Small moleculeDosage Form
2
ALL1
Dry Powder1
TabletLead Product
2
ALL1
Folic Acid1
IronTarget
0
ALLTherapeutic Area : Hematology
Study Phase : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
FDA Infant Formula Update: June 17, 2022
Details : Aptamil (Iron) First Infant Milk Stage 1(This infant formula is appropriate for most infants and meets U.S. nutrient requirements, but it may not be suitable for infants born prematurely, or with a low birth weight.
Brand Name : Aptamil
Molecule Type : Small molecule
Upfront Cash : Not Applicable
June 17, 2022
Therapeutic Area : Hematology
Highest Development Status : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Folic Acid,Iron
Therapeutic Area : Hematology
Study Phase : Approved
Sponsor : Cipla
Deal Size : $12.3 million
Deal Type : Acquisition
Cipla acquires 4 key brands from Wanbury for up to Rs 89 crore.
Details : Cipla has acquired the four brands namely CPink, CDense, Productiv and Folinine to further strengthen its presence in the women's health segment, Cipla said in a filing to the BSE.
Brand Name : Undisclosed
Molecule Type : Small molecule
Upfront Cash : Undisclosed
February 07, 2020
Lead Product(s) : Folic Acid,Iron
Therapeutic Area : Hematology
Highest Development Status : Approved
Sponsor : Cipla
Deal Size : $12.3 million
Deal Type : Acquisition
LOOKING FOR A SUPPLIER?